文献速递脑血管病

脑出血后抗血小板治疗的长期随访:RESTART随机试验

Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage: Extended Follow-up of the RESTART Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2021-01-01

RESTART试验延长随访至中位3.0年,评估脑出血后启动抗血小板治疗的安全性。

要点

  • 脑出血后启动抗血小板治疗未显著增加复发性脑出血风险
  • 抗血小板治疗对主要血管事件无显著影响
  • 若二级预防有指征,抗血小板治疗可提供一定 reassurance

核心结论

  • 在既往接受抗血栓治疗的脑出血患者中,抗血小板治疗对复发性脑出血或所有主要血管事件无统计学显著影响。

研究设计与样本

  • 前瞻性、开放标签、盲法终点、平行组随机临床试验,纳入英国122家医院的537例18岁以上患者,随机分配至启动或避免抗血小板治疗。

临床怎么用

  • 对于脑出血后需二级预防主要血管事件的患者,抗血小板治疗可考虑使用,但需个体化评估。

局限性

  • 研究为开放标签设计,可能引入偏倚;事件数较少,置信区间较宽,不能排除临床重要差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The Restart or Stop Antithrombotics Randomized Trial (RESTART) found that antiplatelet therapy appeared to be safe up to 5 years after intracerebral hemorrhage (ICH) that had occurred during antithrombotic (antiplatelet or anticoagulant) therapy. OBJECTIVES: To monitor adherence, increase duration of follow-up, and improve precision of estimates of the effects of antiplatelet therapy on recurrent ICH and major vascular events. DESIGN, SETTING AND PARTICIPANTS: From May 22, 2013, through May 31, 2018, this prospective, open, blinded end point, parallel-group randomized clinical trial studied 537 participants at 122 hospitals in the UK. Participants were individuals 18 years or older who had taken antithrombotic therapy for the prevention of occlusive vascular disease when they developed ICH, discontinued antithrombotic therapy, and survived for 24 hours. After initial follow-up ended on November 30, 2018, annual follow-up was extended until November 30, 2020, for a median of 3.0 years (interquartile range [IQR], 2.0-5.0 years) for the trial cohort. INTERVENTIONS: Computerized randomization that incorporated minimization allocated participants (1:1) to start or avoid antiplatelet therapy. MAIN OUTCOMES AND MEASURES: Participants were followed up for the primary outcome (recurrent symptomatic ICH) and secondary outcomes (all major vascular events) for up to 7 years. Data from all randomized participants were analyzed using Cox proportional hazards regression, adjusted for minimization covariates. RESULTS: A total of 537 patients (median age, 76.0 years; IQR, 69.0-82.0 years; 360 [67.0%] male; median time after ICH onset, 76.0 days; IQR, 29.0-146.0 days) were randomly allocated to start (n = 268) or avoid (n = 269 [1 withdrew]) antiplatelet therapy. The primary outcome of recurrent ICH affected 22 of 268 participants (8.2%) allocated to antiplatelet therapy compared with 25 of 268 participants (9.3%) allocated to avoid antiplatelet therapy (adjusted hazard ratio, 0.87; 95% CI, 0.49-1.55; P = .64). A major vascular event affected 72 participants (26.8%) allocated to antiplatelet therapy compared with 87 participants (32.5%) allocated to avoid antiplatelet therapy (hazard ratio, 0.79; 95% CI, 0.58-1.08; P = .14). CONCLUSIONS AND RELEVANCE: Among patients with ICH who had previously taken antithrombotic therapy, this study found no statistically significant effect of antiplatelet therapy on recurrent ICH or all major vascular events. These findings provide physicians with some reassurance about the use of antiplatelet therapy after ICH if indicated for secondary prevention of major vascular events. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN71907627.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Al-Shahi Salman R, Dennis MS, Sandercock PAG, et al. Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage: Extended Follow-up of the RESTART Randomized Clinical Trial. JAMA Neurol. 2021. PMID: 34477823. doi:10.1001/jamaneurol.2021.2956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。